GLAXO news

• 03-Nov-2026 18:49:16

  GLAXOSMITHKLINE PHARMACEUTICALS Q2 FY27 ; NET PROFIT UP 30% AT ₹336 CR (YOY), UP 42% (QOQ)

  REVENUE UP 21% AT ₹1,184 CR (YOY), UP 26% (QOQ) EBITDA UP 20% AT ₹402 CR (YOY), UP 36% (QOQ) MARGINS AT 34.0% VS 34.3% (YOY), 31.5% (QOQ)

• 03-Nov-2026 18:49:10

  GSKPHARMA Q2 : CONS NET PROFIT UP 30.4% AT ₹335.88 CR (YOY), UP 41.6% (QOQ). STRONG (ON 1ST LOOK)

  Revenue up 20.8% at ₹1183.57 Cr (YOY), up 26.1% (QOQ). Ebitda up 28.6% at ₹474.85 Cr (YOY), up 40.0% (QOQ); margins 40.1% v 37.7% (YOY), 36.2% (QOQ). Caution:…

← Back to feed